Newron's Evenamide Data Takes Center Stage at Key Psychiatry Conference

Newron presents critical Evenamide data for treatment-resistant schizophrenia at SIRS 2026, alongside Phase III trial updates and board changes, as shares face pressure.

All eyes are on Newron SpA this week as the biopharmaceutical company prepares to unveil fresh clinical data for its drug candidate, Evenamide. The presentations at the SIRS Congress in Florence, scheduled for March 25–29, 2026, arrive at a critical juncture for the firm. The central question for investors and clinicians alike is whether this compound can emerge as a viable treatment for schizophrenia patients who do not respond to existing therapies.

A Novel Mechanism Targeting Glutamate

Evenamide represents a distinct therapeutic approach. It diverges from conventional antipsychotics, which primarily target the dopamine system. Instead, Evenamide modulates glutamate release through the selective blockade of voltage-gated sodium channels, a mechanism that leaves basal glutamate levels unaffected. This unique action profile positions it as a potential adjunctive therapy, even for individuals with an inadequate response to clozapin.

Beyond this, Newron will share new findings from a neurodevelopmental animal model of schizophrenia at the conference. These results suggest the possibility of long-term clinical benefits.

An Update on Advanced Clinical Trials

The Florence congress will also serve as a platform for Newron to provide a progress report on its ENIGMA-TRS Phase III program. This initiative comprises two actively recruiting studies:

• ENIGMA-TRS 1: This one-year, placebo-controlled trial, which began in August 2025, involves a minimum of 600 participants. It is evaluating Evenamide at doses of 15 mg and 30 mg, administered twice daily.
• ENIGMA-TRS 2: A 12-week study launched in December 2025, this trial will enroll at least 400 patients to assess a 15 mg twice-daily regimen of Evenamide.

Both investigations are examining the drug as an add-on treatment for treatment-resistant schizophrenia. Their endpoints extend beyond core symptom reduction to include measurements of social functioning and patient quality of life.

Corporate Calendar and Board Changes

Separate from the scientific meeting, Newron has several corporate events on the horizon. The company’s Annual General Meeting is set for April 23, 2026. The full agenda, alongside the 2025 financial results and the 2026 outlook, will be published on March 24.

The board of directors will see a change in composition. Two long-serving members, Patrick Langlois and Luca Benatti, will not stand for re-election. Newron has nominated George Garibaldi and Paolo Zocchi to join the board as new independent directors.

Market Context and Investor Sentiment

Newron's shares have faced significant pressure in recent weeks, shedding approximately one-third of their value over the past 30 trading days. The current share price sits notably below its 50-day moving average of €21.70. Against this backdrop, the data presentations in Florence are anticipated to deliver the first concrete indication of whether the Phase III program can generate the positive momentum the market is awaiting.